"TORONTO, Dec. 17, 2018 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX® (daratumumab), in combination with bortezomib, melphalan and prednisone (VMP), for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplantation.3 DARZALEX® is the first monoclonal antibody to be approved for newly diagnosed patients in Canada".
https://www.newswire.ca/news-releases/health-canada-approves-darzalex-daratumumab-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible-702919241.html
https://www.newswire.ca/news-releases/health-canada-approves-darzalex-daratumumab-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible-702919241.html
